Broad and potent neutralizing antibody responses elicited in natural HIV-2 infection

Journal of Virology

Volumn 86, Issue 2, 2012, Pages 947-960

  Kong, Rui ^a   Li, Hui ^b   Bibollet Ruche, Frederic ^b   Decker, Julie M ^a   Zheng, Natalie N ^c   Gottlieb, Geoffrey S ^c   Kiviat, Nancy B ^c   Sow, Papa Salif ^d   Georgiev, Ivelin ^e   Hahn, Beatrice H ^b   Kwong, Peter D ^e   Robinson, James E ^f   Shaw, George M ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d Centre Hospitalier Universitaire Dakar   (Senegal)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; EPITOPE; GLYCOPROTEIN GP 120; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

ANTIBODY RESPONSE; ARTICLE; BINDING SITE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; GENE AMPLIFICATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; IC 50; MAJOR CLINICAL STUDY; MURINE LEUKEMIA VIRUS; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; VESICULAR STOMATITIS VIRUS; VIRUS GENOME; VIRUS NEUTRALIZATION; VIRUS STRAIN;

AMINO ACID SEQUENCE; ANTIBODIES, NEUTRALIZING; ANTIBODY FORMATION; CELL LINE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP160; HIV INFECTIONS; HIV-1; HIV-2; HUMANS; MOLECULAR SEQUENCE DATA; PHYLOGENY; SEQUENCE ALIGNMENT;

HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; MURINE LEUKEMIA VIRUS; VESICULAR STOMATITIS VIRUS;

EID: 84863115725     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06155-11     Document Type: Article

References (66)

1. Barnett SW, Quiroga M, Werner A, Dina D, Levy JA. 1993. Distinguishing features of an infectious molecular clone of the highly divergent and noncytopathic human immunodeficiency virus type 2 UC1 strain. J. Virol. 67:1006-1014.
2. Behrendt R, et al. 2009. A neutralization assay for HIV-2 based on measurement of provirus integration by duplex real-time PCR. J. Virol. Methods 159:40-46.
3. Binley JM, et al. 2008. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J. Virol. 82: 11651-11668.
4. Bjorling E, et al. 1993. Autologous neutralizing antibodies prevail in HIV-2 but not in HIV-1 infection. Virology 193:528-530.
5. Bohne-Lang A, von der Lieth CW. 2005. GlyProt: in silico glycosylation of proteins. Nucleic Acids Res. 33:W214-W219.
6. Cardoso RM, et al. 2005. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 22:163-173.
7. Chen L, et al. 2009. Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science 326:1123-1127.
8. Cole KS, et al. 2001. Characterization of neutralization epitopes of simian immunodeficiency virus (SIV) recognized by rhesus monoclonal antibodies derived from monkeys infected with an attenuated SIV strain. Virology 290:59-73.
9. Damond F, et al. 2008. Quality control assessment of human immunodeficiency virus type 2 (HIV-2) viral load quantification assays: results from an international collaboration on HIV-2 infection in 2006. J. Clin. Microbiol. 46:2088-2091.
10. da Silva ZJ, et al. 2008. Changes in prevalence and incidence of HIV-1, HIV-2 and dual infections in urban areas of Bissau, Guinea-Bissau: is HIV-2 disappearing? AIDS 22:1195-1202.
11. Davis KL, et al. 2009. Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma. J. Virol. 83:1240-1259.
12. Davis KL, et al. 2009. High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination. Virology 387:414-426.
13. Decker JM, et al. 2005. Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J. Exp. Med. 201:1407-1419.
14. Decker JM, et al. 2009. Effective activation alleviates the replication block of CCR5-tropic HIV-1 in chimpanzee CD4+lymphocytes. Virology 394: 109-118.
15. Derdeyn CA, et al. 2000. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J. Virol. 74:8358-8367.
16. de Silva TI, Cotten M, Rowland-Jones SL. 2008. HIV-2: the forgotten AIDS virus. Trends Microbiol. 16:588-595.
17. de Silva TI, et al. 2012. Potent autologous and heterologous neutralizing antibody responses occur in HIV-2 infection across a broad range of infection outcomes. J. Virol. 86:930-946.
18. Ferns RB, Garson JA. 2006. Development and evaluation of a real-time RT-PCR assay for quantification of cell-free human immunodeficiency virus type 2 using a brome mosaic virus internal control. J. Virol. Methods 135:102-108.
19. Gao F, et al. 1994. Genetic diversity of human immunodeficiency virus type 2: evidence for distinct sequence subtypes with differences in virus biology. J. Virol. 68:7433-7447.
20. Gao F, Yue L, Sharp PM, Hahn BH. 1993. Genetic typing of HIV-2 from a Senegalese/German heterosexual transmission. AIDS Res. Hum. Retroviruses 9:703-704.
21. Gao F, et al. 1992. Human infection by genetically diverse SIVSM-related HIV-2 in West Africa. Nature 358:495-499.
22. Gnanakaran S, et al. 2010. Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies. PLoS Comput. Biol. 6:e1000955.
23. Gottlieb GS, et al. 2002. Equal plasma viral loads predict a similar rate of CD4+T cell decline in human immunodeficiency virus (HIV) type 1- and HIV-2-infected individuals from Senegal, West Africa. J. Infect. Dis. 185: 905-914.
24. Gray ES, et al. 2009. Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region. J. Virol. 83:11265-11274.
25. Gray ES, et al. 2009. Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. J. Virol. 83:8925-8937.
26. Hahn BH, Shaw GM, De Cock KM, Sharp PM. 2000. AIDS as a zoonosis: scientific and public health implications. Science 287:607-614.
27. Hamel DJ, et al. 2007. Twenty years of prospective molecular epidemiology in Senegal: changes in HIV diversity. AIDS Res. Hum. Retroviruses 23:1189-1196.
28. Keele BF, et al. 2008. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. U. S. A. 105:7552-7557.
29. Keele BF, et al. 2009. Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J. Exp. Med. 206:1117-1134.
30. Kong LI, et al. 1988. West African HIV-2-related human retrovirus with attenuated cytopathicity. Science 240:1525-1529.
31. Kwong PD, et al. 2002. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420: 678-682.
32. Kwong PD, Wilson IA. 2009. HIV-1 and influenza antibodies: seeing antigens in new ways. Nat. Immunol. 10:573-578.
33. Kwong PD, et al. 1998. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393:648-659.
34. Lemey P, et al. 2003. Tracing the origin and history of the HIV-2 epidemic. Proc. Natl. Acad. Sci. U. S. A. 100:6588-6592.
35. Louder MK, et al. 2005. HIV-1 envelope pseudotyped viral vectors and infectious molecular clones expressing the same envelope glycoprotein have a similar neutralization phenotype, but culture in peripheral blood mononuclear cells is associated with decreased neutralization sensitivity. Virology 339:226-238.
36. Mascola JR, Montefiori DC. 2010. The role of antibodies in HIV vaccines. Annu. Rev. Immunol. 28:413-444.
37. Palmer S, et al. 2005. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J. Clin. Microbiol. 43:406-413.
38. Pancera M, et al. 2010. Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. Proc. Natl. Acad. Sci. U. S. A. 107:1166-1171.
39. Pantophlet R, Burton DR. 2006. GP120: target for neutralizing HIV-1 antibodies. Annu. Rev. Immunol. 24:739-769.
40. Piatak M, Jr, et al. 1993. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 259:1749-1754.
41. Reeves JD, Doms RW. 2002. Human immunodeficiency virus type 2. J. Gen. Virol. 83:1253-1265.
42. Ren X, Sodroski J, Yang X. 2005. An unrelated monoclonal antibody neutralizes human immunodeficiency virus type 1 by binding to an artificial epitope engineered in a functionally neutral region of the viral envelope glycoproteins. J. Virol. 79:5616-5624.
43. Richman DD, Wrin T, Little SJ, Petropoulos CJ. 2003. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. U. S. A. 100:4144-4149.
44. Robinson JE, et al. 1998. Production and characterization of SIV envelope-specific rhesus monoclonal antibodies from a macaque asymptomatically infected with a live SIV vaccine. AIDS Res. Hum. Retroviruses 14:1253-1262.
45. Robinson JE, Holton D, Pacheco-Morell S, Liu J, McMurdo H. 1990. Identification of conserved and variant epitopes of human immunodeficiency virus type 1 (HIV-1) gp120 by human monoclonal antibodies produced by EBV-transformed cell lines. AIDS Res. Hum. Retroviruses 6:567-579.
46. Rodriguez SK, et al. 2007. Comparison of heterologous neutralizing antibody responses of human immunodeficiency virus type 1 (HIV-1)-and HIV-2-infected Senegalese patients: distinct patterns of breadth and magnitude distinguish HIV-1 and HIV-2 infections. J. Virol. 81: 5331-5338.
47. Rowland-Jones SL, Whittle HC. 2007. Out of Africa: what can we learn from HIV-2 about protective immunity to HIV-1? Nat. Immunol. 8:329-331.
48. Rusert P, et al. 2011. Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against crossneutralizing antibodies. J. Exp. Med. 208:1419-1433.
49. Salazar-Gonzalez JF, et al. 2008. Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by singlegenome amplification and sequencing. J. Virol. 82:3952-3970.
50. Salazar-Gonzalez JF, et al. 2009. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J. Exp. Med. 206:1273-1289.
51. Schief WR, Ban YE, Stamatatos L. 2009. Challenges for structure-based HIV vaccine design. Curr. Opin. HIV AIDS 4:431-440.
52. Seaman MS, et al. 2010. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J. Virol. 84: 1439-1452.
53. Shi Y, et al. 2005. Evolution of human immunodeficiency virus type 2 coreceptor usage, autologous neutralization, envelope sequence and glycosylation. J. Gen. Virol. 86:3385-3396.
54. Shriner D, Rodrigo AG, Nickle DC, Mullins JI. 2004. Pervasive genomic recombination of HIV-1 in vivo. Genetics 167:1573-1583.
55. Sigal A, et al. 2011. Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature 477:95-98.
56. Simmonds P, Balfe P, Ludlam CA, Bishop JO, Brown AJ. 1990. Analysis of sequence diversity in hypervariable regions of the external glycoprotein of human immunodeficiency virus type 1. J. Virol. 64:5840-5850.
57. Tamalet C, et al. 1995. Autologous neutralizing antibodies and viral load in HIV-2-infected individuals. AIDS 9:90-91.
58. Wei X, et al. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46:1896-1905.
59. Wei X, et al. 2003. Antibody neutralization and escape by HIV-1. Nature 422:307-312.
60. Weiss RA, et al. 1988. HIV-2 antisera cross-neutralize HIV-1. AIDS 2:95-100.
61. Wu X, et al. 2011. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333:1593-1602.
62. Wyatt R, Sodroski J. 1998. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280:1884-1888.
63. Zhang M, et al. 2004. Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. Glycobiology 14:1229-1246.
64. Zheng NN, et al. 2007. Role of human immunodeficiency virus (HIV)-specific T-cell immunity in control of dual HIV-1 and HIV-2 infection. J. Virol. 81:9061-9071.
65. Zhou JY, Montefiori DC. 1997. Antibody-mediated neutralization of primary isolates of human immunodeficiency virus type 1 in peripheral blood mononuclear cells is not affected by the initial activation state of the cells. J. Virol. 71:2512-2517.
66. Zwick MB, et al. 2001. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 75:10892-10905.